Search

Your search keyword '"Haddad, Elias V."' showing total 23 results
Start Over Author "Haddad, Elias V."
23 results on '"Haddad, Elias V."'

1. Trends and Outcomes of Antegrade Dissection and Re-Entry in Chronic Total Occlusion Percutaneous Coronary Intervention

Author

Rempakos, Athanasios, Alexandrou, Michaella, Simsek, Bahadir, Kostantinis, Spyridon, Karacsonyi, Judit, Mutlu, Deniz, Ybarra, Luiz F., Bagur, Rodrigo, Choi, James W., Poommipanit, Paul, Khatri, Jaikirshan J., Davies, Rhian, Benton, Stewart, Gorgulu, Sevket, Jaffer, Farouc A., Chandwaney, Raj, Jaber, Wissam, Rinfret, Stephane, Nicholson, William, Azzalini, Lorenzo, Kearney, Kathleen E., Kerrigan, Jimmy L., Haddad, Elias V., Alaswad, Khaldoon, Basir, Mir B., Krestyaninov, Oleg, Khelimskii, Dmitrii, Abi-Rafeh, Nidal, ElGuindy, Ahmed, Goktekin, Omer, Rangan, Bavana V., Mastrodemos, Olga C., Al-Ogaili, Ahmed, Allana, Salman S., Sandoval, Yader, Burke, M. Nicholas, and Brilakis, Emmanouil S.

Published
2023
Full Text
View/download PDF

2. Impact of calcium on the procedural techniques and outcomes of chronic total occlusion percutaneous coronary intervention

Author

Kostantinis, Spyridon, Rempakos, Athanasios, Simsek, Bahadir, Karacsonyi, Judit, Allana, Salman S., Alexandrou, Michaella, Gorgulu, Sevket, Alaswad, Khaldoon, Basir, Mir Babar, Davies, Rhian E., Benton, Stewart M., Jr, Krestyaninov, Oleg, Khelimskii, Dmitrii, Frizzell, Jarrod, Ybarra, Luiz F., Bagur, Rodrigo, Reddy, Niranjan, Kerrigan, Jimmy L., Haddad, Elias V., Love, Michael, Elbarouni, Basem, Soylu, Korhan, Yildirim, Ufuk, Dattilo, Philip, Azzalini, Lorenzo, Kearney, Kathleen, Sadek, Yasser, ElGuindy, Ahmed M., Abi Rafeh, Nidal, Goktekin, Omer, Mastrodemos, Olga C., Rangan, Bavana V., Sandoval, Yader, Burke, M. Nicholas, and Brilakis, Emmanouil S.

Published
2023
Full Text
View/download PDF

3. List of contributors

Author

Abi Rafeh, Nidal, primary, Agostoni, Pierfrancesco, additional, Akyuz, Sukru, additional, Alaswad, Khaldoon, additional, Ali, Ziad A., additional, Allana, Salman S., additional, Alraies, Chadi, additional, Araya, Mario, additional, Avran, Alexandre, additional, Azzalini, Lorenzo, additional, Babunashvili, Avtandil, additional, Banerjee, Subhash, additional, Bangalore, Sripal, additional, Bayani, Baktash, additional, Behnes, Michael, additional, Bhindi, Ravinay, additional, Boudou, Nicolas, additional, Božinović, Nenad Ž., additional, Bryniarski, Leszek, additional, Bufe, Alexander, additional, Buller, Christopher E., additional, Burke, M. Nicholas, additional, Cardoso, Pedro Pinto, additional, Carlino, Mauro, additional, Cavalcante, Joao L., additional, Chami, Tarek, additional, Chandwaney, Raj H., additional, Charitakis, Konstantinos, additional, Cheng, Victor Y., additional, Choi, James W., additional, Christiansen, Evald Høj, additional, Chugh, Yashasvi, additional, Colombo, Antonio, additional, Cosgrove, Claudia, additional, Croce, Kevin, additional, Daggubati, Ramesh, additional, Damas de los Santos, Félix, additional, Dautov, Rustem, additional, Davies, Rhian E., additional, de Martini, Tony, additional, Denktas, Ali E., additional, Dens, Joseph, additional, di Mario, Carlo, additional, Diletti, Roberto, additional, Dimitriadis, Zisis, additional, Doshi, Darshan, additional, Doshi, Parag, additional, Dou, Kefei, additional, Egred, Mohaned, additional, Elbarouni, Basem, additional, ElGuindy, Ahmed M., additional, Elhadidy, Amr, additional, Ellis, Stephen, additional, Escaned, Javier, additional, Fasseas, Panayotis, additional, Forouzandeh, Farshad, additional, Furkalo, Sergey, additional, Gagnor, Andrea, additional, Galassi, Alfredo R., additional, Gallino, Robert, additional, Garbo, Roberto, additional, Garcia, Santiago, additional, Gasparini, Gabriele, additional, Ge, Junbo, additional, Ge, Lei, additional, Goel, Pravin Kumar, additional, Goktekin, Omer, additional, Gonzalo, Nieves, additional, Gorgulu, Sevket, additional, Grancini, Luca, additional, Grantham, J. Aaron, additional, Guddeti, Raviteja, additional, Haddad, Elias V., additional, Hall, Allison B., additional, Hall, Jack J., additional, Halligan, Sean, additional, Hanna Quesada, Franklin Leonardo, additional, Hanratty, Colm, additional, Harb, Stefan, additional, Harding, Scott A., additional, Hatem, Raja, additional, Hildick-Smith, David, additional, Hill, Jonathan M., additional, Hirai, Taishi, additional, Iannaccone, Mario, additional, Jaber, Wissam, additional, Jaffer, Farouc A., additional, Jang, Yangsoo, additional, Jefferson, Brian K., additional, Jeremias, Allen, additional, Jussila, Risto, additional, Kakouros, Nikolaos, additional, Kalnins, Artis, additional, Kalra, Sanjog, additional, Kalyanasundaram, Arun, additional, Kandzari, David E., additional, Kao, Hsien-Li, additional, Karacsonyi, Judit, additional, Karmpaliotis, Dimitri, additional, Kassem, Hussien Heshmat, additional, Kearney, Kathleen, additional, Kerrigan, Jimmy, additional, Khatri, Jaikirshan, additional, Khelimskii, Dmitrii, additional, Kirtane, Ajay J., additional, Knaapen, Paul, additional, Kostantinis, Spyridon, additional, Koutouzis, Michalis, additional, Kovacic, Mihajlo, additional, Krestyaninov, Oleg, additional, Kumar, A.V. Ganesh, additional, Kumar N., Prathap, additional, Kunkel, Katherine J., additional, Lamelas, Pablo Manuel, additional, Lee, Seung-Whan, additional, Lefevre, Thierry, additional, Leibundgut, Gregor, additional, Lembo, Nicholas J., additional, Leon, Martin, additional, Lesser, John R., additional, Leung, Raymond, additional, Lim, Soo-Teik, additional, Lo, Sidney Tsz Ho, additional, Lombardi, William, additional, Luna, Michael, additional, Mahmud, Ehtisham, additional, Mahowald, Madeline K., additional, Maran, Anbukarasi, additional, Marmagkiolis, Konstantinos, additional, Martins Filho, Evandro, additional, Mashayekhi, Kambis, additional, McEntegart, Margaret B., additional, Megaly, Michael, additional, Meraj, Perwaiz, additional, Michalis, Lampros, additional, Milkas, Anastasios N., additional, Mogabgab, Owen, additional, Moses, Jeffrey, additional, Munawar, Muhammad, additional, Murad, Bilal, additional, Nap, Alexander, additional, Navarro, Andres, additional, Nicholson, William J., additional, Øksnes, Anja, additional, Olivecrona, Göran, additional, Omer, Mohamed A., additional, Oreglia, Jacopo Andrea, additional, Padilla, Lucio, additional, Patel, Mitul P., additional, Patel, Rajan A.G., additional, Patel, Taral, additional, Pershad, Ashish, additional, Pinto, Duane, additional, Poommipanit, Paul, additional, Postu, Marin, additional, Potluri, Srini, additional, Pyxaras, Stylianos, additional, Quadros, Alexandre Schaan de, additional, Ragosta, Michael, additional, Rao, Sunil V., additional, Rao, Vithala Surya Prakasa, additional, Rathore, Sudhir, additional, Reifart, Joerg, additional, Rempakos, Athanasios, additional, Rier, Jeremy, additional, Riley, Robert, additional, Rinfret, Stéphane, additional, Russo, Juan J., additional, Saghatelyan, Meruzhan, additional, Sandhu, Gurpreet S., additional, Sandoval, Yader, additional, Santiago, Ricardo, additional, Sapontis, James, additional, Shah, Alpesh, additional, Shlofmitz, Evan, additional, Shunk, Kendrick A., additional, Sianos, George, additional, Simsek, Bahadir, additional, Smith, Elliot J., additional, Spaedy, Anthony, additional, Spratt, James, additional, Strange, Julian W., additional, Strauss, Bradley, additional, Tajti, Péter, additional, Tamez, Hector, additional, Tammam, Khalid O., additional, Thompson, Craig A., additional, Toma, Aurel, additional, Toma, Catalin, additional, Tsiafoutis, Ioannis, additional, Tsuchikane, Etsuo, additional, Ungi, Imre, additional, Uretsky, Barry F., additional, Vlachojannis, Georgios J., additional, Vo, Minh Nhat, additional, Vu, Hoang Vu, additional, Walsh, Simon, additional, Weilenmann, Daniel, additional, Werner, Gerald, additional, Wójcik, Jarosław, additional, Wollmuth, Jason, additional, Wu, Eugene B., additional, Wyman, R. Michael, additional, Xenogiannis, Iosif, additional, Xu, Bo, additional, Yamane, Masahisa, additional, Ybarra, Luiz F., additional, and Yeh, Robert W., additional

Published
2023
Full Text
View/download PDF

5. Development and validation of a scoring system for predicting clinical coronary artery perforation during percutaneous coronary intervention of chronic total occlusions: the PROGRESS-CTO perforation score

Author

Kostantinis, Spyridon, Şimşek, Bahadır, Karacsonyi, Judit, Alaswad, Khaldoon, Jaffer, Farouc A., Khatri, Jaikirshan J., Choi, James W., Jaber, Wissam, Rinfret, Stephane, Nicholson, William, Patel, Mitul P., Mahmud, Ehtisham, Toma, Catalin, Davies, Rhian E., Kerrigan, Jimmy L., Haddad, Elias V., Görgülü, Şevket, Abi-Rafeh, Nidal, ElGuindy, Ahmed M., Göktekin, Ömer, Allana, Salman, Burke, M. Nicholas, Mastrodemos, Olga C., Rangan, Bavana V., Brilakis, Emmanouil S., and Tıp Fakültesi

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Background: Coronary artery perforation is a feared complication of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) and often leads to serious adverse clinical events. Aims: We sought to develop a risk score to predict clinical coronary artery perforation in patients undergoing CTO PCI. Methods: We analysed clinical and angiographic parameters from 9,618 CTO PCIs in the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO). Logistic regression prediction modelling was used to identify variables independently associated with clinical perforation, and the model was internally validated with bootstrapping. Clinical coronary artery perforation was defined as any perforation requiring treatment. Results: The incidence of clinical coronary perforation was 3.8% (n=367). Five factors were independently associated with perforation and were included in the score: patient age ≥65 years +1 point (odds ratio [OR] 1.79, 95% confidence interval [CI]: 1.37-2.33), moderate/severe calcification +1 point (OR 1.85, 95% CI: 1.41-2.42), blunt/no stump +1 point (OR 1.45, 95% CI: 1.10-1.92), use of antegrade dissection and re-entry +1 point (OR 2.43, 95% CI: 1.61-3.69), and use of the retrograde approach +2 points (OR 4.02, 95% CI: 2.95-5.46). The resulting score showed acceptable performance on receiver operating characteristic (ROC) curve (area under the curve [AUC]: 0.741, 95% CI: 0.712-0.773). The Hosmer-Lemeshow test indicated a good fit (p=0.991), and internal validation with bootstrapping demonstrated good agreement with the model with observed AUC: 0.736 (95% bias-corrected CI: 0.706-0.767). Conclusions: The PROGRESS-CTO perforation score may be a useful tool for predicting clinical coronary perforation during CTO PCI.

Published
2023

7. Incidence, Mechanisms, Treatment, and Outcomes of Coronary Artery Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention

Author

Kostantinis, Spyridon, primary, Simsek, Bahadir, additional, Karacsonyi, Judit, additional, Alaswad, Khaldoon, additional, Krestyaninov, Oleg, additional, Khelimskii, Dmitrii, additional, Karmpaliotis, Dimitri, additional, Jaffer, Farouc A., additional, Khatri, Jaikirshan J., additional, Poommipanit, Paul, additional, Jaber, Wissam A., additional, Rinfret, Stephane, additional, Nicholson, William, additional, Patel, Mitul P., additional, Mahmud, Ehtisham, additional, Koutouzis, Michael, additional, Tsiafoutis, Ioannis, additional, Benton, Stewart M., additional, Davies, Rhian E., additional, Toma, Catalin, additional, Kerrigan, Jimmy L., additional, Haddad, Elias V., additional, Abi-Rafeh, Nidal, additional, ElGuindy, Ahmed M., additional, Goktekin, Omer, additional, Mastrodemos, Olga C., additional, Rangan, Bavana V., additional, Burke, M. Nicholas, additional, and Brilakis, Emmanouil S., additional

Published
2022
Full Text
View/download PDF

8. Same day discharge versus overnight observation following chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS‐CTO registry.

Author

Simsek, Bahadir, Khatri, Jaikirshan, Young, Laura, Kostantinis, Spyridon, Karacsonyi, Judit, Rempakos, Athanasios, Alaswad, Khaldoon, Jaffer, Farouc A., Doshi, Darshan, Gorgulu, Sevket, Goktekin, Omer, Kerrigan, Jimmy, Haddad, Elias V., Rinfret, Stephane, Jaber, Wissam A., Nicholson, William, Krestyaninov, Oleg, Khelimskii, Dimitrii, Choi, James W., and Patel, Taral N.

Published
2023
Full Text
View/download PDF

9. Intravascular lithotripsy in chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS‐CTO registry

Author

Kostantinis, Spyridon, primary, Simsek, Bahadir, additional, Karacsonyi, Judit, additional, Davies, Rhian E., additional, Benton, Stewart, additional, Nicholson, William, additional, Rinfret, Stephane, additional, Jaber, Wissam A., additional, Raj, Leah, additional, Sandesara, Pratik B., additional, Alaswad, Khaldoon, additional, Basir, Mir Babar, additional, Megaly, Michael, additional, Khatri, Jaikirshan J., additional, Young, Laura D., additional, Jaffer, Farouc A., additional, Abi Rafeh, Nidal, additional, Patel, Mitul P., additional, Kerrigan, Jimmy L., additional, Haddad, Elias V., additional, Dattilo, Phil, additional, Sandoval, Yader, additional, Schimmel, Daniel R., additional, Sheikh, Abdul M., additional, ElGuindy, Ahmed M., additional, Goktekin, Omer, additional, Mastrodemos, Olga C., additional, Rangan, Bavana V., additional, Burke, M. Nicholas, additional, and Brilakis, Emmanouil S., additional

Published
2022
Full Text
View/download PDF

10. Predictors of success in primary retrograde strategy in chronic total occlusion percutaneous coronary intervention: insights from the PROGRESS‐chronic total occlusion registry

Author

Simsek, Bahadir, primary, Kostantinis, Spyridon, additional, Karacsonyi, Judit, additional, Alaswad, Khaldoon, additional, Karmpaliotis, Dimitri, additional, Masoumi, Amirali, additional, Jaffer, Farouc A., additional, Doshi, Darshan, additional, Khatri, Jaikirshan, additional, Poommipanit, Paul, additional, Gorgulu, Sevket, additional, Abi Rafeh, Nidal, additional, Goktekin, Omer, additional, Krestyaninov, Oleg, additional, Davies, Rhian, additional, ElGuindy, Ahmed, additional, Haddad, Elias V., additional, Kerrigan, Jimmy, additional, Patel, Mitul, additional, Chandwaney, Raj H., additional, Mastrodemos, Olga C., additional, Allana, Salman, additional, Rangan, Bavana V., additional, and Brilakis, Emmanouil S., additional

Published
2022
Full Text
View/download PDF

22. PGE2 decreases reactivity of human platelets by activating EP2 and EP4

Author

Smith, James P., Haddad, Elias V., Downey, Jason D., Breyer, Richard M., and Boutaud, Olivier

Subjects
*BLOOD platelets, *PROSTAGLANDINS, *LABORATORY mice, *THROMBOSIS, *PROSTACYCLIN, *CELL receptors, *THROMBOXANES, *REVERSE transcriptase polymerase chain reaction
Abstract

Abstract: Introduction: Platelet hyperreactivity associates with cardiovascular events in humans. Studies in mice and humans suggest that prostaglandin E2 (PGE2) regulates platelet activation. In mice, activation of the PGE2 receptor subtype 3 (EP3) promotes thrombosis, but the significance of EP3 in humans is less well understood. Objectives: To characterize the regulation of thromboxane-dependent human platelet activation by PGE2. Patients/Methods: Platelets collected from nineteen healthy adults were studied using an agonist of the thromboxane receptor (U46,619), PGE2, and selective agonists and/or antagonists of the EP receptor subtypes. Platelet activation was assayed by (1) optical aggregometry, (2) measurement of dense granule release, and (3) single-platelet counting. Results: Healthy volunteers demonstrated significant interindividual variation in platelet response to PGE2. PGE2 completely inhibited U46,619-induced platelet aggregation and ATP release in 26% of subjects; the remaining 74% had partial or no response to PGE2. Antagonism of EP4 abolished the inhibitory effect of PGE2. In all volunteers, a selective EP2 agonist inhibited U46,619-induced aggregation. Furthermore, the selective EP3 antagonist DG-041 converted all PGE2 nonresponders to full responders. Conclusions: There is significant interindividual variation of platelet response to PGE2 in humans. The balance between EP2, EP3, and EP4 activation determines its net effect. PGE2 can prevent thromboxane-induced platelet aggregation in an EP4-dependent manner. EP3 antagonism converts platelets of nonresponders to a PGE2-responsive phenotype. These data suggest that therapeutic targeting of EP pathways may have cardiovascular benefit by decreasing platelet reactivity. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

23. Activated clotting time and outcomes of chronic total occlusion percutaneous coronary intervention: insights from the PROGRESS-CTO Registry.

Author

Simsek B, Rempakos A, Kostantinis S, Alexandrou M, Gorgulu S, Alaswad K, Frizzell JD, Yildirim U, Poommipanit P, Aygul N, Abi Rafeh N, Bagur R, Davies R, Goktekin O, Choi JW, Reddy N, Dattilo P, Kerrigan J, Haddad EV, Mastrodemos OC, Rangan BV, Karacsonyi J, Allana SS, Kearney KE, Sandoval Y, Burke MN, Brilakis ES, and Azzalini L

Subjects
Humans, Prospective Studies, Registries, Hospitals, Percutaneous Coronary Intervention adverse effects, Vascular Diseases
Abstract

Background: The optimal range of activated clotting time (ACT) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has received limited study., Methods: We examined the association between ACT and in-hospital ischemic and bleeding outcomes in patients who underwent CTO PCI in the Prospective Global Registry for the Study of CTO Intervention., Results: ACT values were available for 4377 patients who underwent CTO PCI between 2012 and 2023 at 29 centers. The mean ACT distribution was less than 250 seconds (19%), 250 to 349 seconds (50%), and greater than or equal to 350 seconds (31%). The incidence of ischemic events, bleeding events, and net adverse cardiovascular events (NACE) was 0.8%, 3.0%, and 3.8%, respectively. In multiple logistic regression analysis, increasing nadir ACT was associated with decreasing ischemic events (adjusted odds ratio [aOR] per 50-second increments: 0.69 [95% confidence interval (CI), 0.50-0.94; P=.017]; and increasing peak ACT was associated with increasing bleeding events (aOR per 50-second increments: 1.17 [95% CI ,1.01-1.36; P=.032]). A U-shaped association was seen between mean ACT and NACE, where restricted cubic spline analysis demonstrated that patients with a low ( less than 200 seconds) or high ( greater than 400 seconds) ACT had increasing NACE risk compared with an ACT of 200 to 400 seconds (aOR 2.06, 95% CI 1.18-3.62; P=.012)., Conclusions: Among patients who underwent CTO PCI, mean ACT had a U-shaped relationship with NACE, where patients with a low ( less than 200 seconds) ACT (driven by ischemic events) or high ( greater than 400 seconds) ACT (driven by bleeding) had higher NACE compared with an ACT of 200 to 400 seconds.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results